PUBLISHER: KBV Research | PRODUCT CODE: 1093018
PUBLISHER: KBV Research | PRODUCT CODE: 1093018
North America Preimplantation Genetics Diagnosis (PGD) Market Size, Share & Industry Trends Analysis Report By Test Type (Aneuploidy, Chromosomal Abnormalities, X-linked diseases), By Country and Growth Forecast, 2022 - 2028
The North America Preimplantation Genetics Diagnosis (PGD) Market would witness market growth of 8.5% CAGR during the forecast period (2022-2028).
PGD is widely used in in-vitro fertilization genetic testing to detect genetic problems in embryos. PGD has been shown to reduce the likelihood of generating unhealthy embryos. Furthermore, it considerably improves the odds of a healthy pregnancy. In addition, the rise in infertility rates, as well as genetic, hereditary, and chromosomal problems, boosted market expansion. Furthermore, technological improvements in PGD give benefits, such as the capacity to prevent impairment in kids and the generation of unhealthy savior siblings when PGD is combined with HLA. Furthermore, PGD showed a positive response in patients with recurrent IVF failures, low sperm count, and advanced maternal age who were trying to conceive.
In addition, it improves the odds of having a healthy pregnancy. In addition, factors such as increasing intake of alcohol, drugs, smoking, and poor food; increased stress; greater exposure to environmental contaminants; and an increase in health problems linked to hormones have all contributed to an increase in infertility cases around the world. This has increased the usage of IVF, which has had a beneficial impact on the growth of the market. Moreover, benefits such as the development of savior siblings and the increased adoption of assisted reproductive technology (ART) in underdeveloped nations are projected to boost the PGD industry. Furthermore, an increase in the risk of fatal genetic, hereditary, and chromosomal illnesses such as Duchenne muscular dystrophy, Down syndrome, cystic fibrosis, triploidy, and thalassemia encourages patients to choose PGD, thereby boosting the growth of the market.
Abnormalities, which can lead to a variety of genetic illnesses. Aneuploidy is the most common cause of Down syndrome in newborn babies in the United States, which accounts for the majority of the North American market's income. According to a report issued by the World Health Organization in 2018, down syndrome remains the most common chromosomal abnormality, impacting 6,000 newborns born in the United States each year.
As a result, there is a strong demand for earlier detection to detect genetic problems in embryos. More income is generated by important players launching new products and a surge in improvements in healthcare infrastructure in the United States. One of the key trends in the regional market is an increase in government activities to raise public awareness and a growing preference among couples for these tests during IVF and other artificial insemination procedures.
The US market dominated the North America Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $41.8 million by 2028. The Canada market is experiencing a CAGR of 11% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 10% during (2022 - 2028).
Based on Test Type, the market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
Scope of the Study
Market Segments covered in the Report:
By Test Type
- Aneuploidy
- Chromosomal Abnormalities
- X-linked diseases
- Single Gene Disorders
- HLA Typing
- Gender selection
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Illumina, Inc.
- Invitae Corporation
- Natera, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Quest Diagnostics Incorporated
- Reproductive Genetic Innovations
- PacGenomics
- CeGaT GmbH
- Laboratory Corporation of America Holdings
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Preimplantation Genetics Diagnosis (PGD) Market, by Test Type
- 1.4.2 North America Preimplantation Genetics Diagnosis (PGD) Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type
- 3.1 North America Aneuploidy Market by Country
- 3.2 North America Chromosomal Abnormalities Market by Country
- 3.3 North America X-linked diseases Market by Country
- 3.4 North America Single Gene Disorders Market by Country
- 3.5 North America HLA Typing Market by Country
- 3.6 North America Gender selection Market by Country
- 3.7 North America Other Test Type Market by Country
Chapter 4. North America Preimplantation Genetics Diagnosis (PGD) Market by Country
- 4.1 US Preimplantation Genetics Diagnosis (PGD) Market
- 4.1.1 US Preimplantation Genetics Diagnosis (PGD) Market by Test Type
- 4.2 Canada Preimplantation Genetics Diagnosis (PGD) Market
- 4.2.1 Canada Preimplantation Genetics Diagnosis (PGD) Market by Test Type
- 4.3 Mexico Preimplantation Genetics Diagnosis (PGD) Market
- 4.3.1 Mexico Preimplantation Genetics Diagnosis (PGD) Market by Test Type
- 4.4 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market
- 4.4.1 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type
Chapter 5. Company Profiles
- 5.1 Illumina, Inc.
- 5.1.1 Company Overview
- 5.1.2 Financial Analysis
- 5.1.3 Regional Analysis
- 5.1.4 Research & Development Expense
- 5.2 Invitae Corporation
- 5.2.1 Company Overview
- 5.2.2 Financial Analysis
- 5.2.3 Regional Analysis
- 5.2.4 Research & Development Expenses
- 5.3 Natera Inc.
- 5.3.1 Company Overview
- 5.3.2 Financial Analysis
- 5.3.3 Regional Analysis
- 5.3.4 Research & Development Expenses
- 5.4 Agilent Technologies, Inc.
- 5.4.1 Company Overview
- 5.4.2 Financial Analysis
- 5.4.3 Segmental and Regional Analysis
- 5.4.4 Research & Development Expense
- 5.4.5 Recent Strategies and Developments:
- 5.4.5.1 Approvals and Trials:
- 5.5 PerkinElmer, Inc.
- 5.5.1 Company Overview
- 5.5.2 Financial Analysis
- 5.5.3 Segmental and Regional Analysis
- 5.5.4 Research & Development Expense
- 5.5.5 Recent Strategies and Developments:
- 5.5.5.1 Product Launches and Product Expansions:
- 5.6 Quest Diagnostics Incorporated
- 5.6.1 Company Overview
- 5.6.2 Financial Analysis
- 5.6.3 Segmental Analysis
- 5.7 Reproductive Genetic Innovations
- 5.7.1 Company Overview
- 5.8 PacGenomics
- 5.8.1 Company Overview
- 5.9 CeGaT GmbH
- 5.9.1 Company Overview
- 5.10. Laboratory Corporation of America Holdings
- 5.10.1 Company Overview
- 5.10.2 Financial Analysis
- 5.10.3 Segmental and Regional Analysis
LIST OF TABLES
- TABLE 1 North America Preimplantation Genetics Diagnosis (PGD) Market, 2018 - 2021, USD Thousands
- TABLE 2 North America Preimplantation Genetics Diagnosis (PGD) Market, 2022 - 2028, USD Thousands
- TABLE 3 North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2018 - 2021, USD Thousands
- TABLE 4 North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2022 - 2028, USD Thousands
- TABLE 5 North America Aneuploidy Market by Country, 2018 - 2021, USD Thousands
- TABLE 6 North America Aneuploidy Market by Country, 2022 - 2028, USD Thousands
- TABLE 7 North America Chromosomal Abnormalities Market by Country, 2018 - 2021, USD Thousands
- TABLE 8 North America Chromosomal Abnormalities Market by Country, 2022 - 2028, USD Thousands
- TABLE 9 North America X-linked diseases Market by Country, 2018 - 2021, USD Thousands
- TABLE 10 North America X-linked diseases Market by Country, 2022 - 2028, USD Thousands
- TABLE 11 North America Single Gene Disorders Market by Country, 2018 - 2021, USD Thousands
- TABLE 12 North America Single Gene Disorders Market by Country, 2022 - 2028, USD Thousands
- TABLE 13 North America HLA Typing Market by Country, 2018 - 2021, USD Thousands
- TABLE 14 North America HLA Typing Market by Country, 2022 - 2028, USD Thousands
- TABLE 15 North America Gender selection Market by Country, 2018 - 2021, USD Thousands
- TABLE 16 North America Gender selection Market by Country, 2022 - 2028, USD Thousands
- TABLE 17 North America Other Test Type Market by Country, 2018 - 2021, USD Thousands
- TABLE 18 North America Other Test Type Market by Country, 2022 - 2028, USD Thousands
- TABLE 19 North America Preimplantation Genetics Diagnosis (PGD) Market by Country, 2018 - 2021, USD Thousands
- TABLE 20 North America Preimplantation Genetics Diagnosis (PGD) Market by Country, 2022 - 2028, USD Thousands
- TABLE 21 US Preimplantation Genetics Diagnosis (PGD) Market, 2018 - 2021, USD Thousands
- TABLE 22 US Preimplantation Genetics Diagnosis (PGD) Market, 2022 - 2028, USD Thousands
- TABLE 23 US Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2018 - 2021, USD Thousands
- TABLE 24 US Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2022 - 2028, USD Thousands
- TABLE 25 Canada Preimplantation Genetics Diagnosis (PGD) Market, 2018 - 2021, USD Thousands
- TABLE 26 Canada Preimplantation Genetics Diagnosis (PGD) Market, 2022 - 2028, USD Thousands
- TABLE 27 Canada Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2018 - 2021, USD Thousands
- TABLE 28 Canada Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2022 - 2028, USD Thousands
- TABLE 29 Mexico Preimplantation Genetics Diagnosis (PGD) Market, 2018 - 2021, USD Thousands
- TABLE 30 Mexico Preimplantation Genetics Diagnosis (PGD) Market, 2022 - 2028, USD Thousands
- TABLE 31 Mexico Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2018 - 2021, USD Thousands
- TABLE 32 Mexico Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2022 - 2028, USD Thousands
- TABLE 33 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market, 2018 - 2021, USD Thousands
- TABLE 34 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market, 2022 - 2028, USD Thousands
- TABLE 35 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2018 - 2021, USD Thousands
- TABLE 36 Rest of North America Preimplantation Genetics Diagnosis (PGD) Market by Test Type, 2022 - 2028, USD Thousands
- TABLE 37 key information - Illumina, Inc.
- TABLE 38 Key Information - Invitae Corporation
- TABLE 39 Key Information - Natera Inc.
- TABLE 40 key Information - Agilent Technologies, Inc.
- TABLE 41 key Information - PerkinElmer, Inc.
- TABLE 42 Key information - Quest Diagnostics Incorporated
- TABLE 43 Key information - Reproductive Genetic Innovations
- TABLE 44 Key Information - PacGenomics
- TABLE 45 key information - CeGaT GmbH
- TABLE 46 Key Information - Laboratory Corporation of America holdings
List of Figures
- FIG 1 Methodology for the research
